Crossmark

One-point flow cytometric MRD measurement to identify children with excellent outcome after intermediate-risk BCP-ALL: results of the ALL-MB 2008 study

Crossref DOI link: https://doi.org/10.1007/s00432-022-04378-3

Published Online: 2022-09-28

Published Print: 2023-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Popov, Alexander

Henze, Guenter

Roumiantseva, Julia

Budanov, Oleg

Belevtsev, Mikhail

Verzhbitskaya, Tatiana

Boyakova, Elena

Movchan, Liudmila

Tsaur, Grigory

Fadeeva, Maria

Lagoyko, Svetlana

Zharikova, Liudmila

Miakova, Natalia

Litvinov, Dmitry

Khlebnikova, Olga

Streneva, Olga

Stolyarova, Elena

Ponomareva, Natalia

Novichkova, Galina

Fechina, Larisa

Aleinikova, Olga

Karachunskiy, Alexander
License Information

Text and Data Mining valid from 2022-09-28

Version of Record valid from 2022-09-28
More Information

Article History

Received: 19 August 2022

Accepted: 22 September 2022

First Online: 28 September 2022

Declarations

:

: The authors have no relevant financial or non-financial interests to disclose.

: This study was performed in line with the principles of the Declaration of Helsinki. The study was approved by the Ethics Committee of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology.

: Informed consent for the collection and investigation of samples was obtained from patients’ parents or legal guardians.

Document is current

Any future updates will be listed below